Pharsight

Drugs that contain Leuprolide Acetate

1. Eligard Kit patents expiration

ELIGARD KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8470359 TOLMAR THERAP Sustained release polymer
Oct, 2023

(a month ago)

Market Authorisation Date: 13 February, 2003

Treatment: Method of treating cancer

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

ELIGARD KIT family patents

Family Patents

2. Eligard Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11771841 TOLMAR Systems and methods for mixing syringe valve assemblies
Dec, 2041

(18 years from now)

Market Authorisation Date: 23 January, 2002

Treatment: NA

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

ELIGARD KIT family patents

Family Patents

3. Fensolvi Kit patents expiration

FENSOLVI KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8470359 TOLMAR Sustained release polymer
Oct, 2023

(a month ago)

US11771841 TOLMAR Systems and methods for mixing syringe valve assemblies
Dec, 2041

(18 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) May 1, 2023

Market Authorisation Date: 01 May, 2020

Treatment: Method of treating pediatric patients 2 years of age and older with central precocious puberty

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

FENSOLVI KIT family patents

Family Patents

4. Lupron Depot patents expiration

LUPRON DEPOT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815801 ABBVIE ENDOCRINE INC Controlled release composition and method of producing the same
Jun, 2022

(1 year, 5 months ago)

US8921326 ABBVIE ENDOCRINE INC Sustained-release composition and method for producing the same
Feb, 2031

(7 years from now)

Market Authorisation Date: 22 December, 1995

Treatment: Palliative treatment of prostate cancer

Dosage: INJECTABLE;INJECTION

More Information on Dosage

LUPRON DEPOT family patents

Family Patents

5. Lupron Depot-ped Kit patents expiration

LUPRON DEPOT-PED KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9617303 ABBVIE ENDOCRINE INC Sustained-release composition and method for producing the same
Mar, 2028

(4 years from now)

US8921326 ABBVIE ENDOCRINE INC Sustained-release composition and method for producing the same
Feb, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength (NS) Apr 14, 2026

Market Authorisation Date: 16 April, 1993

Treatment: Treatment of pediatric patients with central precocious puberty

Dosage: POWDER;INTRAMUSCULAR

More Information on Dosage

LUPRON DEPOT-PED KIT family patents

Family Patents